Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P900033/S117

INTEGRA Dermal Regeneration Template, Integra Meshed Dermal Regeneration Template, and Integra Omnigraft Dermal Rege

Integra Lifesciences Corp. · Decision date Sep 18, 2026

MEDTECHLEDGER EXPLANATIONP900033/S117

What did the FDA decide?

The record for P900033/S117 describes a 30-Day Notice supplement to PMA P900033, filed by Integra Lifesciences Corp. for the wound and burn interactive dressing product code MGR. The stated purpose is installation and qualification of a new Water for Injection (WFI) pretreatment, generation, storage, and distribution system, filed under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The decision is OK30, dated 2026-09-18.

The source statement identifies only the WFI system scope; it does not name the manufacturing site, the equipment vendor, qualification protocols, or any effect on the finished device. As a supplement to an existing PMA, it is not a new approval of the whole device system, and the notice itself is not evidence of safety or clinical effectiveness. Specifics about the prior WFI system and what changed relative to it are absent from the supplied fields.

FDA approval order statement

installation and qualification of a new Water for Injection (WFI) pretreatment, generation, storage, and distribution system
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
General, Plastic Surgery
Decision date
Sep 18, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P900033/S117
Regulatory pathway
PMA supplement
Product code
MGR
Decision code
OK30
Decision date
Sep 18, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Dressing, wound and burn, interactive.

Product code
MGR
FDA device class
3

For the original device and its historical approval scope, see PMA P900033. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P900033 · Original PMA

    INTEGRA DERMAL REGENERATION TEMPLATE

  2. P900033/S117 received

    Application receipt date recorded by FDA.

  3. P900033/S117 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P900033. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P900033

Product / regulatory recordCompanyPathwayDecision dateSource
Integra Lifesciences Corp.PMA approvalMar 1, 1996FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Integra Lifesciences Corp.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
105 Morgan Ln., Plainsboro, NJ, 08536

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records